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Abstract
Background:  Many genetic variations of GALK1  have been identified in the patients with
galactokinase (GALK1) deficiency. However, the molecular characteristics of GALK1 in individuals
with elevated GALK1 activity are relatively unknown.
Methods: We investigated the relationship between elevated GALK1 activity and the molecular
GALK1 gene variations, and the molecular mechanism underlying elevated GALK1 activity. PCR
products from 63 subjects, without any attenuation of galactose degradation enzymes, were
sequenced to screen for nucleotide alterations in the GALK1 promoter.
Results: Three nucleotide substitutions were identified: c.-179A>G, c.-27A>C, and c.-22T>C.
With respect to the c.-22T>C mutation, GALK1 activity in 13 subjects with the T/C or C/C
genotype was significantly higher than those in 50 subjects with the T/T genotype (p < 0.001). The
dual luciferase reporter assay in Hep3B cells showed that the luciferase activity with the GALK1
promoter with the c.-22C mutant allele increased approximately 2.5-fold, compared to that with
the c.-22T. A specific DNA-protein complex was observed in an electrophoretic mobility shift
assay, with slightly higher affinity to c.-22C than to c.-22T.
Conclusion: The c.-22T>C mutation, which was observed frequently in individuals with elevated
GALK1 activity, increased the expression of a reporter gene through enhanced binding of a
currently unidentified nuclear protein. These results suggest that the elevated GALK1 activity
resulted from enhanced gene expression, due to nucleotide variation within GALK1 promoter.
Background
Galactose is converted into glucose-1-phosphate by the
action of three enzymes: galactokinase (GALK1: EC
2.7.1.6), galactose-1-phosphate uridyltransferase (GALT:
EC 2.7.7.12), and UDP-galactose-4'-epimerase (GALE: EC
5.1.3.2). Galactosemia (MIM 230400, 230350 and
230200) is an autosomal recessive disorder that results
from defects in one of the above enzymes and that affects
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a patient's ability to appropriately metabolize galactose
[1]. The symptoms and severity of the disease vary,
depending on the affected enzyme and the degree of func-
tional defects.
Newborn screening tests for galactosemia have been per-
formed in Korea as well as in many developed countries.
Abnormally low GALT, GALE, or GALK1 activities result
in a positive newborn screen; however, a positive galactos-
emia screening does not indicate only the possibility of
enzyme deficiency, but is perhaps as a reflection of porto-
systemic shunt or liver dysfunction, e.g. citrin deficiency
and Fanconi-Bickel syndrome [2].
Previously, we investigated the phenotypic distribution of
249 Korean patients with a positive newborn screen for
galactosemia and found that elevated GALK1 activity was
observed frequently in these newborns [authors' unpub-
lished data]. In patients with the GALK1 deficiency, vari-
ous nucleotide changes in the coding region of the GALK1
gene have been identified [3-9]. However, no study has
been performed with regard to the molecular characteris-
tics of GALK1 in individuals with increased GALK1 activ-
ity. The exact incidence of GALK1 deficiency is unknown
but is probably 1:1,000,000 [1,4], and the incidence with
elevated GALK1 activity has not been reported.
Interestingly, the enzyme activity of GALK1 changes dur-
ing development: GALK1 activity in newborns is distinctly
high (80–120 nmol/min/g Hb) and decreases sharply
with age until they are one year old (20–30 nmol/min/g
Hb)[10,11] These low values are maintained for the
remainder of life. The GALK1 promoter region is shown to
have high GC content, with several binding sites for the
Sp1 transcription factor, and the absence of TATA-box and
CCAAT-box [12]. During the development of suckling
mouse liver, Egr-1, a transcription factor, was reported to
regulate GALK1 transcription [13]. The presence of puta-
tive binding sites for Egr-1 and Sp1, in the promoter
region of human GALK1 gene, prompted us to speculate
that an increased GALK enzyme activity might be caused
by the transcriptional activation of the GALK1 promoter.
To investigate the relationship between elevated GALK1
activity and transcriptional regulation of GALK1 gene, we
analyzed sequence variations in the promoter region of
the  GALK1  gene, in individuals with elevated GALK1
activity. In addition, we speculate that elevated GALK1
activity could be one of the possible causes for a positive
result for galactosemia in newborn screening.
Methods
Subjects
In Korea, individuals with a positive result in the neonatal
total galactose screening test performed by colorimetric
enzyme assay on dried blood spots, were tested for
GALK1, GALT, and GALE enzyme activities, as well as for
galactose-1-phosphate levels in erythrocytes. Some indi-
viduals showed decreased enzyme activities of GALT,
GALE, and/or GALK1, and these were investigated for the
molecular characteristics of their coding region [9,14].
Sixty-three subjects without any attenuation in galactose
degradation enzymes and with a median age of 29 days
were selected for the present study. Total galactose level by
newborn screening assay on dried blood spots, for all sub-
jects, was 15.3 ± 8.0 mg/dL (mean ± SD, 8.1 – 40.0).
GALK1, GALT, and GALE activities in red blood cells
derived from heparinized whole bloods, were measured
by radiometric assays, which were based on the formation
of radio-labeled galactose-1-phosphate from [14C]galac-
tose and ATP, radio-labeled UDP-galactose from
[14C]galactose-1-phosphate and UDP-glucose, and radio-
labeled UDP-glucose from [14C]UDP-galactose (described
elsewhere), respectively [11]. Galactose-1-phosphate lev-
els in red blood cells were also measured by radiometric
assay [11]. This research was approved by the Institutional
Review Board of the Seoul National University Bundang
Hospital.
PCR and direct sequencing
Human genomic DNA was isolated from frozen white
blood cells, using a HighPure Viral Nucleic Acid Isolation
Kit (Roche Diagnostics, USA). PCR was performed on
genomic DNA to amplify the promoter region (nucleotide
-558 to +71, the translation start site is designated as +1.)
of the GALK1 gene. To cover the promoter region of the
GALK1 gene, two overlapping regions, GKP1 and GKP2,
were amplified using two sets of primers: GKP1-F (5'-CCG
GCC CAA ACT TGT CTC TG-3') and GKP1-R (5'-GTG
GCA GGG GCT AAT GGT G-3'), GKP2-F (5'-TGG TTC TTC
CCG AAG TCC AG-3') and GKP2-R (5'-AAC TCC TCC
CGG AAG GCT C-3'). Up to 50 μL of master mixture was
made, containing 300 ng of genomic DNA, 10 pM of each
primer, 1× PCR buffer, 0.2 mM dNTPs, and 1.25 U Taq
polymerase, for PCR of the first promotor region. For the
second promoter region, 25 mM MgCl2 was added to the
same PCR condition of the first promoter region of
GALK1, with 0.625 U Taq polymerase included. After an
initial denaturation step, at 94°C for 5 min, 30 cycles of
amplification were carried out using the following proce-
dures: denaturation at 94°C for 30 sec, annealing at 61°C
for 30 sec, extension at 72°C for 30 sec (for the amplifica-
tion of GKP1 promoter region or denaturation at 94°C for
1 min), annealing at 56°C for 1 min, and extension at
72°C for 1 min for GKP2, respectively. A final extension
step at 72°C for 5 min also was added. The PCR products
were purified using an ExoSAP-IT (USB corp., OH, USA)
and sequenced using an ABI Prism® BigDye™ Terminator
Cycle Sequencing Ready Reaction Kit v3.1 protocol. DataBMC Medical Genetics 2009, 10:29 http://www.biomedcentral.com/1471-2350/10/29
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were analyzed using an ABI3730XL DNA sequencer
(Applied Biosystems, USA).
PCR and RFLP (restriction fragment length polymorphism)
To confirm the presence of the polymorphisms identified
by sequencing, RFLP was performed on the PCR products.
BsgI (New England Biolabs, MA, USA) restriction enzyme
was used to confirm the c-22T>C mutation on the PCR
products, using the primer pair, GKP2-F and GKP2-R,
which was the same as used for sequencing. However,
PvuII (New England Biolabs, MA, USA) GKP2-R' (5'-CGT
GCA GCC CCT CAC CAT AG-3') primer was used to con-
firm the c.-179A>G and c.-27A>C mutations. We screened
101 healthy adults without any clinical symptoms of
galactosemia to exclude common nucleotide polymor-
phism.
Dual luciferase reporter assay
For this study, the promoter region of the human GALK1
gene (-441 to -1) was cloned into the pGL3-basic firefly
luciferase vector (Promega Corp., WI, USA). Nucleotides
c.-179A, c.-27A, and c.-22T were mutagenized to G, C, and
C, respectively, using a QuikChange Site-directed Muta-
genesis kit (Stratagene, CA, USA). All constructs were con-
firmed by nucleotide sequencing of the entire promoter
region, and all components for cell culture were pur-
chased from JBI (Wel Gene Inc., Korea). Hep3B and
HepG2 cells were grown in Dulbecco's modified Eagle
medium (DMEM), supplemented with 10% fetal calf
serum, penicillin G (100 units/mL), and streptomycin sul-
fate (100 mg/mL). Cells grown in a 60-mm dish were
transfected with plasmids (5 μg of GALK1 promoter in
pGL3-basic and 0.5 μg of pRL-TK vector) using calcium-
phosphate. Cell lysates were prepared and assayed for
luciferase activity, according to the manufacturer's instruc-
tion, using the dual luciferase reporter assay system
(Promega Corp., WI, USA). The assays were performed
five times in duplicate, and the data were normalized by
Renilla luciferase luminescence intensity.
EMSA (electrophoretic mobility shift assay)
Nuclear extracts were prepared as previously described
[15,16], except that all solutions contained 1 mM sodium
vanadate, 1 mM sodium fluoride, and 1× commercial pro-
tease inhibitor cocktail (Boehringer Mannheim Corp.,
Indianopolis, IN). Radio-labeled oligonucleotide probes
[GALK122T (5'-CTG TGC CGG AGC AGC TGT GCA GAG
CTG CAG GCG-3') and GALK122C (5'-CTG TGC CGG
AGC AGC TGC GCA GAG CTG CAG GCG-3')] were pre-
pared as follows: the sense and complementary antisense
oligonucleotides used as probes were synthesized, HPLC
purified, and then annealed in 100 mM NaCl and 50 mM
Tris-HCl pH 7.5, by heating to 90°C for 3 min, and then
cooling to 25°C at 1°C, per 3 min, in the thermal cycler.
Annealed oligonucleotides were end-labeled using T4
polynucleotide kinase and [γ-32P]ATP, by incubation at
37°C for 30 min. Unincorporated radioactive nucleotides
were removed by the QIAquick Nucleotides Removal Kit
(QIAGEN). Four μg of Hep3B nuclear extract was incu-
bated with 20,000 cpm of the labeled probe in a reaction
mixture containing 10 mM HEPES pH 7.9, 100 mM KCl,
0.5 mM EDTA, 100 mM KCl, 6 mM DTT, 5% glycerol, and
2 μg of poly(dI-dC):poly(dI-dC) (Pharmacia Biotech Inc.,
Piscataway, NJ). The binding mixture was incubated at
room temperature for 20 min and run on a 6% nondena-
turing polyacrylamide gel in 1× TBE buffer at 10 V/cm.
The gel was dried at 80°C, under vacuum, and exposed to
an X-ray film. Competition assay was performed with
unlabeled competitor DNA with c.-22C or c.-22T. Super-
shift analysis was performed using anti-HEN1 antibody
(Chemicon International). MatInspector [17] was used to
identify the transcription factors that might bind to the
GALK1 promoter.
Statistical analysis
To standardize GALK1 activity according to patient age,
we obtained the normalized GALK1 value, by dividing
measured GALK1 activity by calculated GALK1 normal
value. Calculated GALK1 normal activity was obtained
according to patient age (less than 6 months) using the
following equation; y = 0.0024x2 - 0.7868x + 105.72
(where x is age in days and y is GALK1 normal activity).
The above quadratic equation was derived from 146 sub-
jects with normal GALK1 activity, and the data are
reported as the mean ± SD (standard deviation). In indi-
viduals with different genotypes, GALK1 activities, their
normalized values, and galactose-1-phosphate levels were
compared using the Mann-Whitney U test. The Spearman
correlation analysis was used to test for unadjusted associ-
ation between GALK1 activities and galactose-1-phos-
phate levels, with statistical significance set at a p value of
0.05. All analyses were performed using the SPSS 12.0 K
for Windows (SPSS Inc., Chicago, IL, USA).
Results
Mutations in the GALK1 promoter region
Sixty-three Koreans with positive newborn screening
results, who did not have any attenuation in galactose
degradation enzymes, were studied. GALK1 activity, for all
subjects, was 113.1 ± 41.5 nmol/min/gHb (mean ± SD,
50.2 – 243.3). We analyzed the underlying molecular
defects of the GALK1 gene using PCR and direct sequenc-
ing. Three nucleotide substitutions were identified in the
promoter region of the GALK1  gene: c.-179A>G, c.-
27A>C, and c.-22T>C (Fig. 1), and the presence of these
polymorphisms was confirmed by performing PCR-RFLP
(Fig. 1). For c.-179A>G, 56 subjects with A/A genotype, 5
with A/G genotype and 2 with G/G genotype were identi-
fied. For c.-27A>C, 61 individuals had A/A genotype and
2 showed A/C genotype. Various genotypes at nucleotideBMC Medical Genetics 2009, 10:29 http://www.biomedcentral.com/1471-2350/10/29
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position c.-179 (A/A, A/G, and G/G) and at c.-27 (A/C and
A/A) were also present in 101 normal individuals, sug-
gesting that two SNPs, c.-179A>G and c.-27A>C, are
benign sequence variations. In terms of c.-22T>C, 50 indi-
viduals with T/T, 12 with T/C, and 1 with C/C genotype
were identified (Table 1). Every individual in the control
group showed the T/T genotype at position c.-22, which
suggests that T to C substitution may be a mutation, rather
than polymorphism. Genotype distributions of the c.-
179A>G, c.-27A>C and c.-22T>C variations did not devi-
ate from those expected for Hardy-Weinberg proportion.
In terms of c.-22 of GALK1, GALK1 activities, and their
normalized values in individuals having at least one C
allele (T/C or C/C genotype), were significantly higher
than those in individuals with T/T genotype (p < 0.001 by
Mann-Whitney U test, respectively) (Table 1 and Fig. 2).
There were statistical differences in GALK1 activities
between subjects with A/A, and those with A/G or G/G, at
c.-179 of the GALK1; however, it disappeared after exclud-
ing 13 individuals with the C allele at c.-22 from total sub-
jects. GALK1 activities in 43 individuals with A/A, versus
in 7 individuals with A/G or GG genotype at position c.-
179 of GALK1, were 98.7 ± 24.1 versus 80.1 ± 20.0 nmol/
min/gHb (p = 0.307). This might be because the C allele
at c.-22 is linked closely with the A allele at c.179. On the
contrary, there was no statistical difference in GALK1
activities between the subjects with A/A and A/C geno-
types at position c.-27 of GALK1 (Table 1), which further
suggests that c.-27A>C is a nonfunctional polymorphism.
Elevated GALK1 activity could result from increased pro-
tein level or from the hyperactivity of the enzyme, without
changes in protein abundance due to amino acid altera-
tion. To test this alternative, we sequenced the PCR prod-
uct of all coding exons of the GALK1  genes for 13
individuals having the C allele at nucleotide -22, accord-
ing to the method described elsewhere [9]. There was no
evidence of nucleotide changes in the coding regions of
GALK1, in the individuals with T/C or C/C genotypes, sug-
gesting that the elevated GALK1 activity is due to
increased GALK1 expression.
To investigate whether elevated GALK1 activity resulting
from -22T>C mutation is associated with an increase of
galactose-1-phosphate in newborns, we measured galac-
tose-1-phosphate levels. Individuals having at least one C
allele (n = 13, 1.59 ± 1.81 mg/dL) showed significantly
higher galactose-1-phosphate levels than did the individ-
uals with c.-22T/T (n = 50, 0.94 ± 1.50 mg/dL) (p = 0.019
by Mann-Whitney U test).
Promoter Analysis of GALK1 Gene
To test if c.-22T>C affected transcription, reporter analysis
was performed using the promoter region of GALK1 gene
(-441 to -1), with nucleotide substitutions at position -
179, -27, and -22. The HepG2 cells transfected with the c.-
22C mutant allele showed an elevated luciferase activity
approximately two-fold over those with the wild type
sequence. This phenomenon appeared more clearly in the
Hep3B cells showing a two and a half fold increase (Fig.
3). In terms of c.-179A>G and c.-27A>C, the relative luci-
ferase activity was not significantly different from that of
the wild type.
EMSA was performed to determine if the elevated luci-
ferase activity of c.-22T>C was due to alterations in the
binding of a nuclear protein. Thirty-three-bp oligonucle-
otides with c.-22T and c.-22C were used as a probe, and
incubation of these radio-labeled probes with Hep3B
nuclear extracts produced a DNA-protein complex (Fig.
4A lanes 2 and 4). When the c-22C DNA-protein complex
was challenged with increasing amounts of cold probes,
the competition was slightly more efficient with c-22C,
Table 1: Genotype distribution of three nucleotide variations in the promoter region of GALK1 gene and their galactokinase values in 
63 subjects
Nucleotide substitution Genotype No. Galactokinase value (nmol/min/gHb) Normalized GALK1 value
mean ± SD p value* mean ± SD p value*
c.-179A>G A/A 56 117.2 ± 41.7 0.012 1.39 ± 2.06 0.001
A/G 5 82.6 ± 23.2 0.99 ± 0.13
G/G 2 73.8 ± 11.8 0.78 ± 0.10
c.-27A>C A/A 61 112.1 ± 41.7 0.173 1.34 ± 0.46 0.473
A/C 2 141.4 ± 27.4 1.47 ± 0.27
C/C 0 - -
c.-22T>C T/T 50 96.1 ± 24.3 <0.001 1.16 ± 0.25 <0.001
T/C 12 176.9 ± 26.9 2.06 ± 0.30
C/C 1 193.6 2.30
p value was determined by SPSS 12.0 by Mann-Whitney testBMC Medical Genetics 2009, 10:29 http://www.biomedcentral.com/1471-2350/10/29
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than with c-22T (Fig. 4A). The competition analysis was
performed three times and the relative band intensity of
the DNA-protein complex was consistently higher when
competed with c-22T than with c-22C (Fig 4B). This result
suggests that the Hep3B nuclear proteins interacted with
the c-22C oligonucleotides with slightly higher affinity
than with the c-22T. MatInspector was utilized to identify
a transcription factor that might differentially interact
with c-22C and c-22T, and HEN1 was identified as a
potential candidate. However, addition of anti-HEN1
antibody did not affect the mobility of the DNA-protein
complex (Fig 1A, lanes 11 and 12). In addition, no super-
shift was observed with anti-Egr1 and anti-Sp1 antibodies
(data not shown).
Discussion
The actions of GALK1 and GALT maintain the level of
galactose-1-phosphate. The increase of galactose-1-phos-
phate, by an abnormal metabolic pathway, may cause var-
ious problems, as galactose-1-phosphate is thought to be
a toxic metabolite [18]. Classic galactosemia is a repre-
sentative disease of an accumulation of galactose-1-phos-
phate, by GALT deficiency, which is known to be the most
common cause of galactosemia [19]. Previously, we
observed elevated GALK1 activity was common in Korean
newborns with a positive neonatal screen result for galac-
tosemia. Unlike GALK1 deficiency, little is known about
the molecular mechanisms that lead to an increase in
GALK1 enzyme activity. In this study, we analyzed 63
newborns with elevated GALK1 activity but without atten-
uated GALT and GALE activities. We found that the nucle-
otide change c.-22T>C in the promoter region of GALK1
gene was highly correlated with elevated GALK1 activity
and galactose-1-phosphate levels possibly by increasing
gene expression.
The luciferase reporter construct containing -441 to -1 of
the GALK1 promoter was able to support the expression of
the reporter gene in hepatoma cell lines, HepG2 and
Hep3B, suggesting that this region has promoter activity.
The reporter construct with c.-22T>C enhanced luciferase
activity, both in the HepG2 and Hep3B cells, where the
fold increase was similar to GALK1 activity seen in the
subjects with the C allele (Table 1). In conjunction with
the EMSA result, this data suggests that the c.-22T>C
resulted in an increased abundance of the GALK1 enzyme,
by facilitating the binding of a currently unidentified
nuclear protein to the promoter region. Interestingly, c.-
Identification of sequence variations in the GALK1 promoter region Figure 1
Identification of sequence variations in the GALK1 promoter region. Sequencing revealed the presence of a mutation 
of c.-22T>C (A). Gel electrophoresis patterns of PCR amplified DNA fragments digested with BsgI for the confirmation of c.-
22T>C (B) are shown (Lane M, DNA size marker; lane 1, C/C; lane2, T/C; lane 3, T/T). BsgI recognizes the sequence 
GTGCAG (underlined in A electrophoretogram) present in wild type c.-22T, but not in c.-22C. The PCR fragment from geno-
type c.-22C/C, c.-22T/C and c.-22T/T will produce (à produce) one (339 bp), three (339, 267 and 72 bp) and two (267 and 72 
bp) bands.BMC Medical Genetics 2009, 10:29 http://www.biomedcentral.com/1471-2350/10/29
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22 is located downstream of most of the transcription
start sites identified by 5'-rapid amplification of cDNA
ends (RACE) PCR [12]. The regulatory element situated
downstream of the transcription start site has also been
documented in genes which lack classical TATA box and
contain CpG-rich regions with multiple transcription start
sites [20].
Enzyme activity can be affected by missense mutations,
resulting in altered amino acid sequence. Various mis-
sense mutations in GALK1, GALT, and GALE genes have
been identified in patients with galactosemia. In addition
to missense mutations, it was found that the -119 to -
116delGTCA of the GALT gene reduced GALT activity by
decreasing GALT transcription [21]. Moreover, the N314D
substitution with a silent L218L substitution is associated
with the 'Los Angeles phenotype', which shows increased
GALT enzyme activity [22]. The suggested mechanism for
increased activity of the LA variant was increased transla-
tion rates, resulting from a favorable codon bias for the
mutated codon. Thus, various mechanisms, including
amino acid sequence change, transcriptional regulation,
and translational regulation, seem to affect the activity of
enzymes involved in galactose metabolism.
The GALK1 activity of human red blood cells is only about
one tenth of that of GALT, and the galactose-1-phosphate
in red blood cells is a minor contributor to the total blood
galactose [23,24]. These findings may suggest that ele-
vated GALK1 activity, with normal GALT activity, has little
influence on the increase of galactose-1-phosphate in
erythrocytes. However, according to a study conducted on
galactose metabolism in intact erythrocytes [10], new-
borns with mean GALK1 levels 3.4 times higher than
adults also showed mean galactose-1-phosphate levels
Distributions of GALK1 activities according to the genotypes  at c.-22 of the GALK1 gene are plotted according to patient  age Figure 2
Distributions of GALK1 activities according to the 
genotypes at c.-22 of the GALK1 gene are plotted 
according to patient age. The GALK1 values for the gen-
otype C/C, T/C, and T/T at nucleotide -22 are indicated as s, 
l, and h, respectively. The GALK1 activities in individuals hav-
ing at least one C allele (T/C or C/C genotype) were signifi-
cantly higher than those in individuals with the T/T genotype 
(p < 0.001 by Mann-Whitney U test).
c.-22T>C mutation resulted in increased reporter activity in hepatoma cell lines Figure 3
c.-22T>C mutation resulted in increased reporter activity in hepatoma cell lines. The promoter region of the 
GALK1 gene was cloned into pGL3-Basic, and the nucleotides at positions c.-179, c.-27, and c.-22 are indicated. Each construct 
was transfected into HepG2 and Hep3B cells five times in duplicate, and dual luciferase assays were performed. The mean luci-
ferase activities, normalized for cell transfection efficiencies, were calculated relative to the activity of the wild type construct 
(wt, set as 100). Standard deviations are indicated. *p < 0.05 and **p < 0.01, significantly different between transfected cell lines 
and wild type by paired t-tests.BMC Medical Genetics 2009, 10:29 http://www.biomedcentral.com/1471-2350/10/29
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which were 3.5 times higher, indicating that transient ele-
vation of GALK1 activity in normal newborns could result
in an increase of galactose-1-phosphate. In the present
study, we found that the -22T>C mutation was associated
with increased GALK1 activity and could increase the
expression of the reporter gene. Moreover, significantly
higher galactose-1-phosphate levels were detected in indi-
viduals with GALK1 containing the 22C allele, even
though they did not have any abnormalities in the GALT
and GALE genes. These findings lead us to speculate that
elevated GALK1 activity resulting from the -22T>C muta-
tion may result in transient accumulation of galactose-1-
phosphate, which in turn might increase the chance of
positive screening results for galactosemia in newborns.
Although individuals with elevated GALK1 activity do not
have a clinical phenotype of classical galactosemia, the
long-term accumulation of toxic galactose 1-phosphate
may cause a minor degree of damage to susceptible
organs, such as the ovary and brain [25]. Further studies
of the identity and the function of nuclear proteins that
bind to the GALK1 promoter, with c.-22T>C, will be nec-
essary to elucidate the mechanism and clinical signifi-
cance of elevated GALK1 activity.
Conclusion
The c.-22T>C of GALK1 gene was frequently observed in
subjects with increased GALK1 activity and this mutation
is thought to be associated with elevated GALK1 activity
probably through promoting GALK1  expression via
enhanced binding of as yet unidentified nuclear protein.
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assay (EMSA). A) The radiolabeled oligonucleotide probes containing c.-22T or c.-22C of the GALK1 gene were incubated 
with Hep3B nuclear extract. When c.-22C was used as a probe, increasing amounts of cold competitors (1, 2, and 5 pmol of c.-
22C and c.-22T) or anti-HEN1 antibody were included as indicated. The DNA-protein complex is indicated with an arrow. B) 
The intensity of the DNA-protein complex in the absence and presence of cold probes, c-22T (h) and c.-22C (n), was meas-
ured using ImageJ. The graph represents means and standard deviations of three independent experiments taking the intensity 
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